Benefits of capecitabine in hormone receptor-positive compared to hormone receptor-negative HER2 normal metastatic breast cancer

被引：0
|
作者：
Altundag, Kadri [1 ]
机构：
[1] Tepe Prime, MKA Breast Canc Clin, TR-06800 Cankaya, Ankara, Turkiye
来源：
MEDICAL ONCOLOGY | 2024年 / 41卷 / 06期
关键词：
MONOTHERAPY;
D O I：
10.1007/s12032-024-02389-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer
    Hoon, Siao-Nge
    Lau, Peter K. H.
    White, Alison M.
    Bulsara, Max K.
    Banks, Patricia D.
    Redfern, Andrew D.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (05):
  • [2] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Zheng, Hongjuan
    Ge, Chenyang
    Lin, Haiping
    Wu, Lunpo
    Wang, Qinghua
    Zhou, Shishi
    Tang, Wanfen
    Zhang, Xia
    Jin, Xiayun
    Xu, Xifeng
    Hong, Zhongwu
    Fu, Jianfei
    Du, Jinlin
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1145 - 1153
  • [3] Estrogen receptor-negative/progesterone receptor-positive and her-2-negative breast cancer might no longer be classified as hormone receptor-positive breast cancer
    Hongjuan Zheng
    Chenyang Ge
    Haiping Lin
    Lunpo Wu
    Qinghua Wang
    Shishi Zhou
    Wanfen Tang
    Xia Zhang
    Xiayun Jin
    Xifeng Xu
    Zhongwu Hong
    Jianfei Fu
    Jinlin Du
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1145 - 1153
  • [4] Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
    Hee Jin Lee
    In Ah Park
    So Yeon Park
    An Na Seo
    Bora Lim
    Yun Chai
    In Hye Song
    Na Eun Kim
    Joo Young Kim
    Jong Han Yu
    Jin-Hee Ahn
    Gyungyub Gong
    [J]. Breast Cancer Research and Treatment, 2014, 145 : 615 - 623
  • [5] Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer
    Lee, Hee Jin
    Park, In Ah
    Park, So Yeon
    Seo, An Na
    Lim, Bora
    Chai, Yun
    Song, In Hye
    Kim, Na Eun
    Kim, Joo Young
    Yu, Jong Han
    Ahn, Jin-Hee
    Gong, Gyungyub
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 615 - 623
  • [6] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Irfan Cicin
    Hakan Karagol
    Ufuk Usta
    Atakan Sezer
    Sernaz Uzunoglu
    Rusen Alas-Cosar
    Tarkan Yetisyigit
    Kazim Uygun
    [J]. Medical Oncology, 2009, 26 : 335 - 343
  • [7] Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer
    Cicin, Irfan
    Karagol, Hakan
    Usta, Ufuk
    Sezer, Atakan
    Uzunoglu, Sernaz
    Alas-Cosar, Rusen
    Yetisyigit, Tarkan
    Uygun, Kazim
    [J]. MEDICAL ONCOLOGY, 2009, 26 (03) : 335 - 343
  • [8] Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer
    Mehta, Rita S.
    Jackson, Donna
    Schubbert, Toni
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3067 - 3068
  • [9] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    [J]. CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [10] Metronomic Schedule of Paclitaxel Is Effective in Hormone Receptor-Positive and Hormone Receptor-Negative Breast Cancer Reply
    Hugh, Judith
    Hanson, John
    Cheang, Maggie
    Nielsen, Torsten
    Perou, Charles
    Dumontet, Charles
    Reed, John
    Krajewska, Maryla
    Treilleux, Isabelle
    Rupin, Matthieu
    Magherini, Emmanuelle
    Mackey, John
    Martin, Miguel
    Vogel, Charles
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) : 3068 - 3069
12345